Ozempic vs Wegovy: What's the Difference? (2026)
Ozempic and Wegovy contain the same active ingredient — semaglutide — but they are prescribed for different conditions, at different doses, and at different price points. Here's how they compare and which one might be right for you.
The Short Answer
Ozempic and Wegovy are both semaglutide made by Novo Nordisk. The key difference: Ozempic is FDA-approved for type 2 diabetes (max 2mg/week), while Wegovy is FDA-approved for weight loss (max 2.4mg/week). Many doctors prescribe Ozempic off-label for weight loss, but Wegovy delivers higher doses and has clinical trial data specifically for weight management.
Same Drug, Different Products
Both Ozempic and Wegovy are manufactured by Novo Nordisk and contain the same active ingredient: semaglutide. Semaglutide is a GLP-1 receptor agonist that mimics the incretin hormone GLP-1, which your body naturally produces after eating. It works by:
- Slowing gastric emptying — food stays in your stomach longer, keeping you full
- Reducing appetite — acting on brain centers that control hunger and satiety
- Improving insulin sensitivity — helping your body process blood sugar more effectively
- Reducing glucagon secretion — lowering the amount of sugar your liver produces
Think of Ozempic and Wegovy like regular-strength and extra-strength versions of the same medication. The formulation is identical — the difference is in the approved dosing range, the FDA indication, and the clinical trial data supporting each product.
FDA-Approved Uses
This is the most important distinction between these two medications:
Type 2 Diabetes
FDA-approved in December 2017 for adults with type 2 diabetes to improve blood sugar control, alongside diet and exercise. Also approved to reduce cardiovascular risk in adults with type 2 diabetes and known heart disease.
Off-label use: Millions of patients use Ozempic for weight loss, but this is not an FDA-approved indication. Insurance may not cover off-label use.
Chronic Weight Management
FDA-approved in June 2021 for chronic weight management in adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related condition. Also approved to reduce cardiovascular risk in adults with established cardiovascular disease.
Specifically designed for weight loss at higher doses with a dedicated titration schedule optimized for weight management.
Dosing Differences
Both medications are administered as a once-weekly subcutaneous injection (under the skin), typically in the abdomen, thigh, or upper arm. The key difference is the maximum dose:
Ozempic follows a titration schedule starting at 0.25mg weekly for the first 4 weeks, then 0.5mg for at least 4 weeks, with a maximum maintenance dose of 2mg per week. Most patients stabilize at 0.5mg or 1mg.
Wegovy has a longer titration schedule designed to minimize side effects: 0.25mg (weeks 1-4), 0.5mg (weeks 5-8), 1mg (weeks 9-12), 1.7mg (weeks 13-16), and a maintenance dose of 2.4mg per week. This 20% higher maximum dose is a significant difference for weight loss outcomes.
Why the dose matters:Clinical trials consistently show that higher semaglutide doses produce greater weight loss. The jump from 2mg (Ozempic's max) to 2.4mg (Wegovy's max) may seem small, but it represents 20% more medication — and the STEP trials demonstrated this translates to meaningfully better weight loss outcomes.
Weight Loss Results: How They Compare
Weight loss is where the rubber meets the road. Here's what the clinical trial data shows:
- -SUSTAIN 1: ~6% at 0.5mg, ~7% at 1mg (30 weeks)
- -SUSTAIN 6: ~7% at 0.5mg, ~10% at 1mg (2 years)
- -Real-world data: 8-14% at 1-2mg doses
Note: SUSTAIN trials were designed for diabetes, not weight loss. Weight loss was a secondary endpoint.
- -STEP 1: ~15% at 2.4mg (68 weeks) vs 2.4% placebo
- -STEP 3 (with lifestyle): ~16% at 2.4mg (68 weeks)
- -STEP 5 (long-term): ~15% sustained at 2 years
STEP trials specifically studied weight loss as the primary endpoint at the 2.4mg dose.
The bottom line: Wegovy produces about 15-17% body weight loss compared to Ozempic's 8-14%. For a 250-pound person, that's roughly 37-42 pounds on Wegovy versus 20-35 pounds on Ozempic. The difference is largely driven by Wegovy's higher 2.4mg dose and the fact that it was studied specifically for weight management in people without diabetes.
Full Comparison Table
| Feature | Ozempic | Wegovy |
|---|---|---|
| Active Ingredient | Semaglutide | Semaglutide |
| Manufacturer | Novo Nordisk | Novo Nordisk |
| FDA Approval | December 2017 | June 2021 |
| Approved For | Type 2 diabetes + CV risk reduction | Chronic weight management + CV risk reduction |
| Dose Range | 0.25mg - 2mg/week | 0.25mg - 2.4mg/week |
| Administration | Weekly injection | Weekly injection (oral also available) |
| Avg. Weight Loss | 8-14% | 15-17% |
| Monthly Cost (no insurance) | ~$998 | ~$1,349 |
| Oral Option | No (Rybelsus is separate) | Yes — $149/mo |
| Insurance Coverage | Good (for diabetes indication) | Growing (many plans now cover for weight loss) |
| Key Clinical Trials | SUSTAIN 1-10, PIONEER | STEP 1-5, SELECT |
| Cardiovascular Benefit | Yes (SUSTAIN 6) | Yes (SELECT trial) |
Prices reflect typical self-pay costs without insurance. Actual costs vary by pharmacy, location, and insurance plan. Last updated March 2026.
Side Effects: Virtually Identical
Because Ozempic and Wegovy contain the same active ingredient, their side effect profiles are nearly identical. The most common side effects are gastrointestinal and tend to occur during dose escalation:
- Nausea (most common, affects 15-44% of patients depending on dose)
- Diarrhea (affects about 15-30%)
- Vomiting (affects about 5-25%)
- Constipation (affects about 10-24%)
- Abdominal pain (affects about 6-20%)
- Headache, fatigue, dizziness (less common)
Side effects at Wegovy's higher 2.4mg dose may be slightly more common or intense compared to lower Ozempic doses. However, the gradual 16-week titration schedule for Wegovy is designed to minimize this. Most patients find side effects improve significantly after the first 4-8 weeks.
Serious but rare side effects for both include pancreatitis, gallbladder problems, kidney issues, and a theoretical (preclinical) risk of thyroid C-cell tumors. Both carry a boxed warning about medullary thyroid carcinoma risk based on animal studies.
Cost and Insurance Coverage
Cost is a major factor in choosing between these medications, and the landscape has shifted significantly in 2025-2026:
Ozempic has a list price of approximately $998 per month without insurance. It is widely covered by insurance for type 2 diabetes. If you are using Ozempic off-label for weight loss, insurance coverage is less predictable — some plans cover it, many do not. Novo Nordisk offers savings programs that can reduce costs for commercially insured patients.
Wegovy injection has a higher list price of approximately $1,349 per month. Insurance coverage for Wegovy has expanded substantially since 2024, with most major commercial insurers now covering it for qualifying patients (BMI 30+ or BMI 27+ with comorbidity). Medicare coverage begins July 2026 under the GLP-1 Bridge program.
Oral Wegovy (semaglutide tablet) launched in January 2026 at a list price of $149 per month for the starting dose, making it by far the most affordable FDA-approved semaglutide option. This has been a game-changer for patients who could not afford injectable options.
Money-saving tip: If you are paying out of pocket and cost is a primary concern, Oral Wegovy at $149/month is now the best value for FDA-approved semaglutide. See our cheapest GLP-1 programs guide for the full breakdown.
Oral Wegovy: The Game Changer
In January 2026, Novo Nordisk launched Oral Wegovy — a daily semaglutide tablet that does not require injections. This fundamentally changes the Ozempic vs Wegovy comparison:
- No needles: Take a daily tablet on an empty stomach with a small sip of water
- Lower cost: Starting at $149/month — less than both injectable Ozempic and Wegovy
- FDA-approved for weight loss: Unlike Ozempic, Oral Wegovy is specifically approved for weight management
- Same active ingredient: Semaglutide in oral formulation with absorption enhancer
- Available doses: 3mg, 7mg, and 14mg daily tablets (titrate up over weeks)
The main trade-off is convenience: a daily tablet versus a once-weekly injection. Some patients prefer the "set it and forget it" nature of weekly injections, while others strongly prefer avoiding needles altogether. There are also specific instructions — you must take it first thing in the morning, 30 minutes before eating or drinking anything else, with no more than 4 ounces of plain water.
Which One Should You Choose?
The best choice depends on your specific situation — your diagnosis, insurance coverage, and preferences. Here is our guidance:
- -You have type 2 diabetes (on-label use, better insurance coverage)
- -Your insurance covers Ozempic but not Wegovy
- -You respond well to lower doses (0.5mg-1mg)
- -Your primary goal is blood sugar control with weight loss as a bonus
- -Weight loss is your primary goal
- -You want access to the higher 2.4mg dose for maximum results
- -You prefer not to inject (Oral Wegovy available)
- -You want a medication specifically approved and studied for weight management
- -Cost is a concern (Oral Wegovy at $149/mo is the cheapest FDA-approved option)
Frequently Asked Questions
Can I switch from Ozempic to Wegovy?
Yes, switching is straightforward since both contain semaglutide. Your doctor will typically match your current Ozempic dose on the Wegovy titration schedule and continue escalating. For example, if you're on Ozempic 1mg, you'd likely start Wegovy at the 1mg step and continue up to 1.7mg, then 2.4mg. There is no washout period needed.
Is Ozempic cheaper than Wegovy?
Injectable Ozempic (~$998/mo) is cheaper than injectable Wegovy (~$1,349/mo) at list price. However, Oral Wegovy launched at $149/mo for the starting dose, making it the cheapest FDA-approved semaglutide product. With insurance, costs vary significantly — Ozempic tends to have better coverage for diabetic patients, while Wegovy coverage for weight loss is expanding.
Does Ozempic work as well as Wegovy for weight loss?
Not quite. Clinical data shows Wegovy produces about 15-17% body weight loss at its maximum 2.4mg dose, compared to Ozempic's 8-14% at lower doses. The difference is primarily driven by Wegovy's higher dosing. Some patients on Ozempic 2mg achieve similar results to lower Wegovy doses, but on average, Wegovy outperforms Ozempic for weight loss.
Can I take Ozempic for weight loss if I don't have diabetes?
Technically, yes — doctors can prescribe Ozempic off-label for weight loss. This is common practice. However, your insurance is less likely to cover it without a diabetes diagnosis. Wegovy is the FDA-approved option specifically for weight management, which means better insurance justification and clinical trial data supporting its use for that purpose.
Are the side effects worse on Wegovy because of the higher dose?
Side effects may be slightly more common or intense at Wegovy's 2.4mg dose compared to lower Ozempic doses. However, Wegovy's extended 16-week titration schedule is designed to minimize this. Most patients tolerate the higher dose well after gradual escalation. The types of side effects (nausea, GI issues) are identical.
What is Oral Wegovy and how does it compare?
Oral Wegovy is a daily semaglutide tablet launched in January 2026 at $149/month. It's FDA-approved for weight loss, requires no injection, and contains the same active ingredient. You take it daily on an empty stomach. It's the most affordable FDA-approved semaglutide option and a strong alternative for patients who dislike needles or cannot afford injectable versions.
Will Ozempic ever be approved for weight loss?
There are no current plans for Novo Nordisk to seek a weight loss indication for Ozempic. Since they already have Wegovy approved for weight management (at a higher price point), there is little business incentive. Ozempic will likely remain approved only for type 2 diabetes, with off-label weight loss use continuing as common practice.
Can I use both Ozempic and Wegovy together?
No. You should never take Ozempic and Wegovy simultaneously, as they contain the same active ingredient (semaglutide). Combining them would result in a dangerous overdose. Your doctor will prescribe one or the other, never both.
Find the Best GLP-1 Provider for You
Compare verified telehealth programs that prescribe Ozempic, Wegovy, and other FDA-approved GLP-1 medications.